Neurocrine Biosciences Inc (NBIX)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	341,300	385,900	339,200	369,700	249,700	191,000	176,400	64,000	154,500	58,200	12,200	71,400	89,600	444,800	364,700	402,000	407,300	93,400	204,800	176,500
Total assets	US$ in thousands	3,718,700	3,535,000	3,305,000	3,472,400	3,251,400	2,848,200	2,613,100	2,359,800	2,368,700	2,143,400	2,005,700	2,144,500	2,072,500	2,017,300	1,956,400	1,846,400	1,734,700	1,502,600	1,515,600	1,361,900
ROA		9.18%	10.92%	10.26%	10.65%	7.68%	6.71%	6.75%	2.71%	6.52%	2.72%	0.61%	3.33%	4.32%	22.05%	18.64%	21.77%	23.48%	6.22%	13.51%	12.96%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $341,300K ÷ $3,718,700K
= 9.18%

The return on assets (ROA) for Neurocrine Biosciences Inc has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ROA started at a relatively high level of 12.96% in March 2020 and peaked at 23.48% in December 2020.

Subsequently, there was a decline in ROA to 4.32% by December 2021, followed by a gradual recovery to 10.26% in June 2024. Notably, the ROA fluctuated within the range of 0.61% to 22.05% during this period, indicating variations in the company's efficiency in generating profits from its assets.

The downward trend observed in the latter part of the period, with a ROA of 9.18% by December 31, 2024, suggests potential challenges or inefficiencies in asset utilization that may require attention and strategic management decisions to improve overall profitability. However, it is essential to consider other financial metrics and factors influencing the company's performance for a more comprehensive assessment of its financial health and operational effectiveness.